BioSpace News Archive

Median Technologies announced that the Company will be participating in the prestigious 2023 European Society for Medical Oncology Congress, set to take place in Madrid, Spain.

On October 13, 2023, Pfizer Inc., a collaboration partner of BioNTech SE, announced a non-cash charge for inventory write-offs and other charges related to COMIRNATY of $0.9 billion.

HUTCHMED Limited announces that new and updated clinical data from several ongoing studies of fruquintinib, in combination with chemotherapies and/or immunotherapies, will be presented at the upcoming European Society for Medical Oncology Congress 2023, taking place on October 20-24, 2023 in Madrid, Spain.

Atom Bioscience announced completion of a D-round financing of approximately $83 million for completion of global pivotal clinical trials of ABP-671, its unique orally administered URAT1 inhibitor for chronic gout.

Enterome announced that updated data from its Phase 1/2 SPENCER study on EO2401, in combination with nivolumab in patients with adrenal tumors, will be presented in an oral session at the European Society for Medical Oncology Congress 2023, to take place on October 20-23, 2023 in Madrid, Spain.

Rockwell Medical, Inc. announced that it will release its financial and operational results for the third quarter ended September 30, 2023 on Tuesday, November 14, 2023.

IDEAYA Biosciences, Inc. announces initiation of a Phase 2 expansion of the darovasertib and crizotinib combination in GNAQ/11 metastatic cutaneous melanoma.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced positive results of a clinical study demonstrating subcutaneous administration of 10 mL of a representative biologic product co-formulated with its ENHANZE® drug delivery technology, in approximately 30 seconds.

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Ms. S. Mishima Gerhart as Chief Regulatory Officer.

CymaBay Therapeutics, Inc. announced the grant of inducement awards to two employees on October 13, 2023 in connection with the employees’ commencement of employment at CymaBay.